Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific schedules for RSUs and stock options priced at $31.26 per share. This move supports Arcutis' growth in immuno-dermatology by attracting key talent. The company continues to develop treatments for chronic inflammatory skin diseases with a robust product pipeline.
Arcutis Biotherapeutics' inducement grants come amid a health sector where 83 of 150 US stocks traded on Pluang rose and 67 fell as of Nov 07, 2026 03:21 WIB. Among notable movers, BKD dropped 15.31% to USD 9.15 with a typical hold time of 11 days and 100% buy order activity, HALO fell 15.10% to USD 104.39 with 100% sell order activity and a 4-day hold, and NTRA declined 13.68% to USD 314.00 with 87% sell orders and an 11-day hold. This snapshot provides context for readers following Arcutis Biotherapeutics' developments.
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Ipsen has disclosed its monthly update on the total number of shares and voting rights as of October 31, 2026. The company reported 83,814,526 shares composing the share capital, with a gross total of 132,059,377 voting rights and a net total of 130,...
At its 2026 International User Summit, Chery unveiled its Globalization 3.0 strategy, moving beyond export-driven growth to emphasize deep localization, sustainable development, and community engagement. The company is expanding local R&D, manufactur...
Ipsen Pharma has disclosed the total number of shares and voting rights composing its capital as of October 31, 2026. The company reported 83,814,526 shares and a gross total of 132,059,377 voting rights, with a net total of 130,677,690 after excludi...
